Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Bought by Diversified Trust Co

Diversified Trust Co lifted its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 177.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,086 shares of the medical research company's stock after acquiring an additional 5,170 shares during the quarter. Diversified Trust Co's holdings in Bio-Rad Laboratories were worth $1,969,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. GeoWealth Management LLC increased its stake in shares of Bio-Rad Laboratories by 342.9% during the fourth quarter. GeoWealth Management LLC now owns 93 shares of the medical research company's stock worth $31,000 after acquiring an additional 72 shares during the period. Picton Mahoney Asset Management increased its stake in shares of Bio-Rad Laboratories by 55.6% during the fourth quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock worth $32,000 after acquiring an additional 35 shares during the period. Curat Global LLC acquired a new position in shares of Bio-Rad Laboratories during the first quarter worth about $34,000. Cape Investment Advisory Inc. acquired a new position in shares of Bio-Rad Laboratories during the fourth quarter worth about $38,000. Finally, Brown Brothers Harriman & Co. increased its stake in shares of Bio-Rad Laboratories by 2,928.6% during the fourth quarter. Brown Brothers Harriman & Co. now owns 212 shares of the medical research company's stock worth $70,000 after acquiring an additional 205 shares during the period. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Bio-Rad Laboratories Price Performance

Shares of NYSE:BIO opened at $243.99 on Friday. The business's 50 day simple moving average is $235.44 and its 200-day simple moving average is $275.24. The firm has a market capitalization of $6.64 billion, a price-to-earnings ratio of -3.20 and a beta of 0.93. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.99 and a quick ratio of 4.43. Bio-Rad Laboratories, Inc. has a 12 month low of $211.43 and a 12 month high of $387.99.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical research company reported $2.54 EPS for the quarter, topping the consensus estimate of $1.73 by $0.81. The business had revenue of $585.40 million for the quarter, compared to analyst estimates of $573.01 million. Bio-Rad Laboratories had a positive return on equity of 4.32% and a negative net margin of 85.16%. The company's quarterly revenue was down 4.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.30 EPS. As a group, equities analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on BIO shares. Wall Street Zen lowered shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Sunday, June 8th. Wells Fargo & Company decreased their price objective on shares of Bio-Rad Laboratories from $260.00 to $245.00 and set an "equal weight" rating on the stock in a report on Monday, June 9th. Royal Bank Of Canada lowered their target price on shares of Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. Citigroup reduced their price target on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Finally, UBS Group decreased their price target on Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $324.25.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.